See more : JKN Global Group Public Company Limited (JKN.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Omega Diagnostics Group PLC (ODX.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omega Diagnostics Group PLC, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Bengal Energy Ltd. (BNG.TO) Income Statement Analysis – Financial Results
- Nixxy, Inc. (NIXX) Income Statement Analysis – Financial Results
- Hindustan Media Ventures Limited (HMVL.NS) Income Statement Analysis – Financial Results
- Tan Delta Systems plc (TAND.L) Income Statement Analysis – Financial Results
- Reunert Limited (RNRTY) Income Statement Analysis – Financial Results
Omega Diagnostics Group PLC (ODX.L)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.omegadiagnostics.com
About Omega Diagnostics Group PLC
Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries and the Far East, Africa, and the Middle East. The company operates through two segments, Health and Nutrition, and Global Health and Other. The Health and Nutrition segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Global Health and Other segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment offers VISITECT CD4, an advanced disease rapid test, which is used to treat patients with HIV; and AbC-19, a COVID-19 antibody testing kit, as well as COVID-19 antigen and antibody testing solutions. The company offers its products to hospitals, clinics, laboratories, and healthcare practitioners through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.55M | 8.54M | 8.73M | 9.82M | 8.76M | 13.55M | 14.25M | 12.74M | 12.11M | 11.59M | 11.26M | 11.12M | 7.90M | 6.20M | 5.44M | 3.49M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.00M | 3.44M | 4.28M | 3.52M | 3.12M | 5.36M | 5.03M | 4.61M | 4.43M | 4.22M | 4.21M | 4.12M | 3.20M | 2.58M | 2.09M | 1.59M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.55M | 5.10M | 4.46M | 6.29M | 5.63M | 8.19M | 9.22M | 8.14M | 7.67M | 7.37M | 7.05M | 7.00M | 4.71M | 3.62M | 3.34M | 1.90M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 46.98% | 59.75% | 51.04% | 64.10% | 64.32% | 60.45% | 64.73% | 63.84% | 63.39% | 63.58% | 62.62% | 62.96% | 59.55% | 58.33% | 61.49% | 54.35% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 487.00K | 250.00K | 210.00K | 226.00K | 137.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.76M | 4.44M | 6.60M | 5.37M | 4.70M | 6.92M | 6.43M | 5.92M | 5.28M | 4.74M | 4.45M | -2.42M | 2.03M | 1.71M | 1.56M | 1.60M | 0.00 | 56.00K | 79.00K |
| Selling & Marketing | 1.53M | 1.26M | 1.48M | 1.49M | 1.53M | 2.29M | 2.12M | 1.82M | 1.89M | 2.10M | 2.30M | 4.44M | 1.07M | 801.00K | 566.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.29M | 5.69M | 8.08M | 6.87M | 6.23M | 9.21M | 8.56M | 7.74M | 7.17M | 6.84M | 6.75M | 2.02M | 3.10M | 2.51M | 2.13M | 1.60M | 0.00 | 56.00K | 79.00K |
| Other Expenses | 0.00 | 0.00 | -301.82K | -257.93K | -324.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 0.00 |
| Operating Expenses | 6.26M | 5.69M | 7.78M | 6.61M | 5.90M | 9.18M | 8.53M | 7.47M | 7.00M | 6.84M | 6.75M | 6.33M | 4.57M | 3.31M | 2.69M | 1.60M | 0.00 | 56.00K | 79.00K |
| Cost & Expenses | 10.26M | 9.13M | 12.06M | 10.13M | 9.03M | 14.54M | 13.55M | 12.07M | 11.43M | 11.07M | 10.96M | 10.45M | 7.77M | 5.89M | 4.79M | 3.19M | 0.00 | 56.00K | 79.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 11.00 | 751.00 | 1.45K | 16.23K | 41.91K | 44.69K | 2.49K | 11.00K | 2.00K | 0.00 | 6.00K | 13.00K | 0.00 | 7.00K | 6.00K |
| Interest Expense | 13.00K | 21.00K | 218.09K | 251.81K | 97.09K | 36.35K | 39.98K | 24.15K | 30.62K | 28.98K | 32.44K | 18.00K | 32.00K | 47.00K | 107.00K | 109.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 591.00K | 1.29M | 886.40K | 1.15M | 473.19K | 624.58K | 597.76K | 631.74K | 703.65K | 679.86K | 675.25K | 680.00K | 337.00K | 212.00K | 184.00K | 119.00K | 0.00 | 43.00K | 6.00K |
| EBITDA | -2.12M | 697.00K | -2.44M | 838.90K | 201.86K | -365.01K | 1.29M | 1.32M | 1.42M | 1.25M | 983.46K | 1.34M | 466.00K | 468.00K | 648.00K | 353.00K | 0.00 | -49.00K | -73.00K |
| EBITDA Ratio | -28.15% | 8.16% | -27.88% | 8.54% | 2.31% | -2.69% | 9.08% | 10.34% | 11.72% | 10.80% | 8.73% | 12.01% | 5.90% | 7.55% | 11.92% | 10.11% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.72M | -592.00K | -3.32M | -313.23K | -271.34K | -6.88M | 694.76K | 669.76K | 672.97K | 527.33K | 306.65K | 517.00K | 136.00K | 307.00K | 573.00K | 298.00K | 0.00 | -92.00K | -79.00K |
| Operating Income Ratio | -35.98% | -6.93% | -38.03% | -3.19% | -3.10% | -50.75% | 4.88% | 5.26% | 5.56% | 4.55% | 2.72% | 4.65% | 1.72% | 4.95% | 10.54% | 8.53% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -537.00K | -358.00K | -218.09K | -7.98M | -97.07K | -35.60K | -38.53K | -7.93K | 11.29K | 15.72K | -30.42K | -38.00K | -31.00K | -97.00K | -306.00K | -174.00K | 0.00 | 7.00K | 6.00K |
| Income Before Tax | -3.25M | -950.00K | -3.54M | -8.30M | -368.42K | -6.91M | 656.23K | 661.83K | 684.26K | 543.04K | 276.22K | 479.00K | 105.00K | 210.00K | 267.00K | 124.00K | 0.00 | -85.00K | -73.00K |
| Income Before Tax Ratio | -43.10% | -11.13% | -40.53% | -84.51% | -4.21% | -51.02% | 4.61% | 5.19% | 5.65% | 4.68% | 2.45% | 4.31% | 1.33% | 3.39% | 4.91% | 3.55% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -80.00K | 459.00K | -1.44M | -1.47M | -28.89K | 355.63K | -57.04K | 89.92K | -54.79K | -149.81K | -306.04K | -48.00K | 74.00K | 23.00K | 46.00K | -114.00K | 0.00 | 0.00 | 0.00 |
| Net Income | -3.86M | -1.41M | -2.10M | -6.83M | 974.25K | -7.27M | 713.26K | 571.91K | 739.05K | 692.85K | 582.27K | 527.00K | 31.00K | 187.00K | 221.00K | 238.00K | 0.00 | -85.00K | -73.00K |
| Net Income Ratio | -51.15% | -16.50% | -24.09% | -69.54% | 11.13% | -53.64% | 5.01% | 4.49% | 6.11% | 5.98% | 5.17% | 4.74% | 0.39% | 3.02% | 4.06% | 6.82% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.01 | -0.01 | -0.05 | 0.01 | -0.06 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 | -0.30 | -0.26 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.05 | 0.01 | -0.06 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.02 | 0.00 | -0.30 | -0.26 |
| Weighted Avg Shares Out | 231.26M | 182.64M | 171.69M | 142.05M | 128.55M | 122.99M | 110.10M | 110.10M | 110.10M | 105.35M | 86.28M | 86.28M | 38.76M | 18.38M | 15.55M | 10.05M | 2.35M | 282.91K | 282.91K |
| Weighted Avg Shares Out (Dil) | 231.84M | 187.00M | 177.10M | 142.10M | 128.71M | 124.35M | 111.13M | 110.89M | 110.94M | 106.41M | 86.33M | 86.30M | 38.76M | 18.86M | 15.55M | 10.81M | 2.56M | 282.91K | 282.91K |
Source: https://incomestatements.info
Category: Stock Reports